Filing Flows › Crispr Therapeutics AG (CRSP) › Q4 2025
Crispr Therapeutics AG (CRSP) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 12, 2026
Crispr Therapeutics AG (CRSP) reported revenue of $864K for the fourth quarter 2025 (Q4 2025), -98% from a year earlier and -3% from the quarter before.
Crispr Therapeutics AG, Q4 2025: revenue $864K (-98% year over year), net loss $131M, operating cash flow −$92.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $864K | -3% | -98% |
| Operating profit | −$155M | — | — |
| Net earnings | −$131M | — | — |
| Operating cash flow | −$92.6M | — | — |
What changed
Revenue was $864K in Q4 2025, down 98% year over year and down 3% from the previous quarter.
Operating costs exceeded revenue by $154.8M, an operating margin of -17912.5%. Total costs grew 55% against a revenue fall of 98%. The fastest-growing cost line was Other operating costs (+416%). The quarter ended with a net loss of $130.6M, wider than the previous quarter's $106.4M loss.
Operating cash flow was −$92.6M. Non-cash charges added back $5.7M of depreciation and amortization and $18.1M of share-based compensation. Working capital and other items added $14.3M. Capital expenditures of $517K exceeded it, leaving free cash flow of −$93.1M.
Questions
What was Crispr Therapeutics AG's revenue in the fourth quarter 2025?
Crispr Therapeutics AG (CRSP) reported revenue of $864K for the fourth quarter 2025 (Q4 2025), -98% from a year earlier and -3% from the quarter before.